Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 74, Issue 4

Drug susceptibility profiles of isolated in the state of São Paulo, 2008–2024 Open Access

Abstract

Infections caused by , an environmentally prevalent, rapidly growing mycobacteria, are increasingly frequent in developed countries.

To analyse the drug susceptibility profiles of isolated in the state of São Paulo from 2008 to 2024.

Of the 2,402 . isolates identified during those 17 years, 558 (23.2%) met the American Thoracic Society’s microbiologic and clinical criteria for drug susceptibility testing (DST), which was performed for five agents – clarithromycin, amikacin, cefoxitin, ciprofloxacin, and doxycycline.

Clarithromycin showed a dramatic increase in resistance phenotype from ≤10% in the early period to 73–90% over the last 8 years. Over half those isolates demonstrated inducible resistance. Resistance to amikacin was found in fewer than 5% of isolates from 2016 to 2021. In 2022, that result increased to 13%, but for 2023 and 2024, it had fallen back to 2%. Over the past decade, cefoxitin DST has reported the majority of isolates as intermediate, a problematic result in . group (MAG) infections, which typically require long-term treatment for successful outcomes. Since 2018, the annual susceptibility rate has been ≤18%, and in five of the 7 years, ≤7%. Ciprofloxacin was typically assessed as susceptible from 2009 to 2011, then decreased sharply to ≤20% over the next several years, and since 2018, the rate has been less than 5%. Through the entire study, doxycycline resistance has remained consistently high; in the years since 2018, ≤6% of isolates have been susceptible.

This study demonstrates wide variation among MAG clinical isolates in the frequency of susceptibility, both across different agents and within individual agents over time. These results emphasize the importance of performing high-quality DST on MAG clinical isolates and suggest the need to consider revising the standard panel of drugs tested.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): minimal inhibitory concentration , non-tuberculous mycobacteria and resistance
© 2025 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.002005
2025-04-15
2025-04-23
Loading full text...

Full text loading...

/deliver/fulltext/jmm/74/4/jmm002005.html?itemId=/content/journal/jmm/10.1099/jmm.0.002005&mimeType=html&fmt=ahah

References

  1. Falkinham JO III, Norton CD, LeChevallier MW. Factors influencing numbers of Mycobacterium avium, Mycobacterium intracellulare, and other Mycobacteria in drinking water distribution systems. Appl Environ Microbiol 2001; 67:1225–1231 [View Article] [PubMed]
     [Google Scholar]
  2. van Ingen J, Boeree MJ, Dekhuijzen PNR, van Soolingen D. Environmental sources of rapid growing nontuberculous mycobacteria causing disease in humans. Clin Microbiol Infect 2009; 15:888–893 [View Article] [PubMed]
     [Google Scholar]
  3. Falkinham JO. Impact of human activities on the ecology of nontuberculous mycobacteria. Future Microbiol 2010; 5:951–960 [View Article] [PubMed]
     [Google Scholar]
  4. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367–416 [View Article] [PubMed]
     [Google Scholar]
  5. Medjahed H, Gaillard J-L, Reyrat J-M. Mycobacterium abscessus: a new player in the mycobacterial field. Trends Microbiol 2010; 18:117–123 [View Article] [PubMed]
     [Google Scholar]
  6. Shallom SJ, Gardina PJ, Myers TG, Sebastian Y, Conville P et al. New rapid scheme for distinguishing the subspecies of the Mycobacterium abscessus group and identification of Mycobacterium Massiliense with inducible clarithromycin resistance. J Clin Microbiol 2013; 51:2943–2949 [View Article] [PubMed]
     [Google Scholar]
  7. De Groote MA, Huitt G. Infections due to rapidly growing mycobacteria. Clinc Infct Dis 2006; 42:1756–1763 [View Article]
     [Google Scholar]
  8. Jarzembowski JA, Young MB. Nontuberculous mycobacterial infections. Arch Pathol Lab Med 2008; 132:1333–1341 [View Article] [PubMed]
     [Google Scholar]
  9. Brown-Elliott BA, Philley JV. Rapidly growing mycobacteria. Microbiol Spectr 2017; 5: [View Article] [PubMed]
     [Google Scholar]
  10. Zhou L, Xu D, Liu H, Wan K, Wang R et al. Trends in the prevalence and antibiotic resistance of Non-tuberculous mycobacteria in Mainland China, 2000-2019: systematic review and meta-analysis. Front Public Health 2020; 8:295 [View Article] [PubMed]
     [Google Scholar]
  11. Maurer FP, Castelberg C, von Braun A, Wolfensberger A, Bloemberg GV et al. Postsurgical wound infections due to rapidly growing mycobacteria in Swiss medical tourists following cosmetic surgery in Latin America between 2012 and 2014. Euro Surveill 2014; 19: [View Article]
     [Google Scholar]
  12. Toy BR, Frank PJ. Outbreak of Mycobacterium abscessus infection after soft tissue augmentation. Dermatol Surg 2003; 29:971–973 [View Article] [PubMed]
     [Google Scholar]
  13. Everall I, Nogueira CL, Bryant JM, Sánchez-Busó L, Chimara E et al. Genomic epidemiology of a national outbreak of post-surgical Mycobacterium abscessus wound infections in Brazil. Microb Genom 2017; 3:e000111 [View Article]
     [Google Scholar]
  14. Furuya EY, Paez A, Srinivasan A, Cooksey R, Augenbraun M et al. Outbreak of Mycobacterium abscessus wound infections among “lipotourists” from the United States who underwent abdominoplasty in the dominican republic. Clinc Infect Dis 2008; 46:1181–1188 [View Article] [PubMed]
     [Google Scholar]
  15. Yuan J, Liu Y, Yang Z, Cai Y, Deng Z et al. Mycobacterium abscessus post-injection abscesses from extrinsic contamination of multiple-dose bottles of normal saline in a rural clinic. Int J Infect Dis 2009; 13:537–542 [View Article] [PubMed]
     [Google Scholar]
  16. Song JY, Sohn JW, Jeong HW, Cheong HJ, Kim WJ et al. An outbreak of post-acupuncture cutaneous infection due to Mycobacterium abscessus. BMC Infect Dis 2006; 6: [View Article]
     [Google Scholar]
  17. Koh S-J, Song T, Kang YA, Choi JW, Chang KJ et al. An outbreak of skin and soft tissue infection caused by Mycobacterium abscessus following acupuncture. Clin Microbiol Infect 2010; 16:895–901 [View Article] [PubMed]
     [Google Scholar]
  18. Nakanaga K, Hoshino Y, Era Y, Matsumoto K, Kanazawa Y et al. Multiple cases of cutaneous Mycobacterium massiliense infection in a “Hot Spa” in Japan. J Clin Microbiol 2011; 49:613–617 [View Article]
     [Google Scholar]
  19. Viana-Niero C, Lima KVB, Lopes ML, da Silva Rabello MC, Marsola LR et al. Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures. J Clin Microbiol 2008; 46:850–855 [View Article]
     [Google Scholar]
  20. Leão SC, Viana-Niero C, Matsumoto CK, Lima KVB, Lopes ML et al. Epidemic of surgical-site infections by a single clone of rapidly growing mycobacteria in Brazil. Future Microbiol 2010; 5:971–980 [View Article]
     [Google Scholar]
  21. Lorena NS de O, Pitombo MB, Côrtes PB, Maya MCA, Silva MG da et al. Mycobacterium massiliense BRA100 strain recovered from postsurgical infections: resistance to high concentrations of glutaraldehyde and alternative solutions for high level disinfection. Acta Cir Bras 2010; 25:455–459 [View Article] [PubMed]
     [Google Scholar]
  22. Nunes L de S, Baethgen LF, Ribeiro MO, Cardoso CM, de Paris F et al. Outbreaks due to Mycobacterium abscessus subsp. bolletii in southern Brazil: persistence of a single clone from 2007 to 2011. J Med Microbiol 2014; 63:1288–1293 [View Article] [PubMed]
     [Google Scholar]
  23. Guimarães T, Chimara E, do Prado GVB, Ferrazoli L, Carvalho NGF et al. Pseudooutbreak of rapidly growing mycobacteria due to Mycobacterium abscessus subsp bolletii in a digestive and respiratory endoscopy unit caused by the same clone as that of a countrywide outbreak. Am J Infect Control 2016; 44:e221–e226 [View Article] [PubMed]
     [Google Scholar]
  24. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J 2020; 56:2000535 [View Article] [PubMed]
     [Google Scholar]
  25. Rominski A, Schulthess B, Müller DM, Keller PM, Sander P. Effect of β-lactamase production and β-lactam instability on MIC testing results for Mycobacterium abscessus. J Antimicrob Chemother 2017; 72:3070–3078 [View Article] [PubMed]
     [Google Scholar]
  26. Clinical and Laboratory Standards Institute Susceptibility Testing of Mycobacteria, Nocardia Spp., and Other Aerobic Actinomycetes. 3rd edition CLSI document M24; 2018
     [Google Scholar]
  27. Gayathri R, Therese KL, Deepa P, Mangai S, Madhavan H. Antibiotic susceptibility pattern of rapidly growing mycobacteria. J Postgrad Med 2010; 56:76–78 [View Article]
     [Google Scholar]
  28. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53:1367–1376 [View Article] [PubMed]
     [Google Scholar]
  29. Wallace RJ Jr, Meier A, Brown BA, Zhang Y, Sander P et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 1996; 40:1676–1681 [View Article] [PubMed]
     [Google Scholar]
  30. Renvoisé A, Brossier F, Galati E, Veziris N, Sougakoff W et al. Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex. Antimicrob Agents Chemother 2015; 59:7153–7155 [View Article] [PubMed]
     [Google Scholar]
  31. Mougari F, Loiseau J, Veziris N, Bernard C, Bercot B et al. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. J Antimicrob Chemother 2017; 72:1669–1677 [View Article]
     [Google Scholar]
  32. Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev 2020; 6:CD010004 [View Article] [PubMed]
     [Google Scholar]
  33. Wallace RJ Jr, Brown-Elliott BA, McNulty S, Philley JV, Killingley J et al. Macrolide/Azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest 2014; 146:276–282 [View Article] [PubMed]
     [Google Scholar]
  34. Clinical and Laboratory Standards Institute (CSLI) Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard-second edition. NCCLS document M24-A2 (ISBN I-56238-746-4); 2011
  35. Ramis IB, Cnockaert M, Von Groll A, Mathys V, Simon A et al. Evaluation of the speed-oligo mycobacteria assay for the identification of nontuberculous mycobacteria. J Med Microbiol 2015; 64:283–287 [View Article] [PubMed]
     [Google Scholar]
  36. Garcia de Carvalho NF, Sato DN, Pavan FR, Ferrazoli L, Chimara E. Resazurin microtiter assay for clarithromycin susceptibility testing of clinical isolates of Mycobacterium abscessus group. Clinical Laboratory Analysis 2016; 30:751–755 [View Article]
     [Google Scholar]
  37. Mann CM, Markham JL. A new method for determining the minimum inhibitory concentration of essential oils. J Appl Microbiol 1998; 84:538–544 [View Article]
     [Google Scholar]
  38. World Health Organization Strategic and Technical Advisory Group for Tuberculosis: Report on Conclusions and Recommendations. Geneva: WHO; 2009
  39. Ramis IB, Cnockaert M, von Groll A, Nogueira CL, Leão SC et al. Antimicrobial susceptibility of rapidly growing mycobacteria using the rapid colorimetric method. Eur J Clin Microbiol Infect Dis 2015; 34:1403–1413 [View Article]
     [Google Scholar]
  40. Clinical and Laboratory Standards Institute Clinical and laboratory standards institute. performance standards for susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes.1st edition. CLSI document M62; 2018
  41. Chimara E, Ferrazoli L, Ueky SYM, Martins MC, Durham AM et al. Reliable identification of mycobacterial species by PCR-restriction enzyme analysis (PRA)-hsp65 in a reference laboratory and elaboration of a sequence-based extended algorithm of PRA-hsp65patterns. BMC Microbiol 2008; 8:48 [View Article]
     [Google Scholar]
  42. He G, Wu L, Zheng Q, Jiang X. Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract. Ann Med 2022; 54:2500–2510 [View Article] [PubMed]
     [Google Scholar]
  43. Kumar K, Daley CL, Griffith DE, Loebinger MR. Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments. Eur Respir Rev 2022; 31:210–212 [View Article] [PubMed]
     [Google Scholar]
  44. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 2012; 67:810–818 [View Article] [PubMed]
     [Google Scholar]
  45. Marques LRM, Ferrazoli L, Chimara E. Pulmonary mycobacteriosis: presumptive diagnosis by international microbiological criteria adopted in the state of São paulo. J Bras Pneumol 2011; 45: [View Article]
     [Google Scholar]
  46. Brazil, Ministry of Health Manual of recommendations for laboratory diagnosis of tuberculosis and mycobacteria non-tuberculosis of interest in public health in brazil; 2022 https://www.gov.br/aids/pt-br/central-de-conteudo/publicacoes/2022/manual-de-recomendacoes-para-o-diagnostico-laboratorial-de-tuberculose-e-micobacterias-nao-tuberculosas-de-interesse-em-saude-publica-no-brasil
  47. Stout JE, Floto RA. Treatment of Mycobacterium abscessus. all macrolides are equal, but perhaps some are more equal than others. Am J Respir Crit Care Med 2012; 186:822–823 [View Article] [PubMed]
     [Google Scholar]
  48. Bailey M, Chettiath T, Mankin AS. Induction of erm (C) expression by noninducing antibiotics. Antimicrob Agents Chemother 2008; 52:866–874 [View Article]
     [Google Scholar]
  49. Nash KA, Brown-Elliott BA, Wallace RJ. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53:1367–1376 [View Article] [PubMed]
     [Google Scholar]
  50. Maurer FP, Rüegger V, Ritter C, Bloemberg GV, Böttger EC. Acquisition of clarithromycin resistance mutations in the 23S rrna gene of Mycobacterium abscessus in the presence of inducible erm(41). J Antimicrob Chemother 2012; 67:2606–2611 [View Article] [PubMed]
     [Google Scholar]
  51. Brown-Elliott BA. Chapter: laboratory diagnosis and antimicrobial susceptibility testing of nontuberculous mycobacteria. In Grriffith D. eds Nontuberculous Mycobacterial Disease: A Comprehensive Approach to Diagnosis and Management. Respiratory Medicine vol 2019 Humana Press; 2019 pp 15–59 [View Article]
     [Google Scholar]
  52. Guo Q, Chu H, Ye M, Zhang Z, Li B et al. The clarithromycin susceptibility genotype affects the treatment outcome of patients with Mycobacterium abscessus lung disease. Antimicrob Agents Chemother 2018; 62:e02360-17 [View Article] [PubMed]
     [Google Scholar]
  53. Kobayashi T, Tsuyuguchi K, Yoshida S, Kurahara Y, Ikegami N et al. Mycobacterium abscessus subsp. abscessus lung disease: drug susceptibility testing in sputum culture negative conversion. Int J Mycobacteriol 2018; 7:69–75 [View Article] [PubMed]
     [Google Scholar]
  54. Park Y, Park YE, Jhun BW, Park J, Kwak N et al. Impact of susceptibility to injectable antibiotics on the treatment outcomes of Mycobacterium abscessus pulmonary disease. Open Forum Infect Dis 2021; 8:215 [View Article]
     [Google Scholar]
  55. Koh W-J, Jeon K, Lee NY, Kim B-J, Kook Y-H et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011; 183:405–410 [View Article] [PubMed]
     [Google Scholar]
  56. Kim HS, Lee KS, Koh W-J, Jeon K, Lee EJ et al. Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy. Radiology 2012; 263:260–270 [View Article]
     [Google Scholar]
  57. Pasipanodya JG, Ogbonna D, Ferro BE, Magombedze G, Srivastava S et al. Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence. Antimicrob Agents Chemother 2017; 61:1206–1217 [View Article]
     [Google Scholar]
  58. Lee SH, Yoo HK, Kim SH, Koh W-J, Kim CK et al. The drug resistance profile of Mycobacterium abscessus group strains from Korea. Ann Lab Med 2014; 34:31–37 [View Article] [PubMed]
     [Google Scholar]
  59. Daniel-Wayman S, Shallom S, Azeem N, Olivier KN, Zelazny AM et al. Amikacin exposure and susceptibility of macrolide-resistant Mycobacterium abscessus. ERJ Open Res 2019; 5:00154–02018 [View Article] [PubMed]
     [Google Scholar]
  60. Cho EH, Huh HJ, Song DJ, Lee SH, Kim CK et al. Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens. Diagn Microbiol Infect Dis 2019; 93:107–111 [View Article] [PubMed]
     [Google Scholar]
  61. Heidarieh P, Mirsaeidi M, Hashemzadeh M, Feizabadi MM, Bostanabad SZ et al. In vitro antimicrobial susceptibility of nontuberculous mycobacteria in Iran. Microb Drug Resist 2016; 22:172–178 [View Article] [PubMed]
     [Google Scholar]
  62. Lee M-C, Sun P-L, Wu T-L, Wang L-H, Yang C-H et al. Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan. J Antimicrob Chemother 2017; 72:2782–2786 [View Article] [PubMed]
     [Google Scholar]
  63. Hatakeyama S, Ohama Y, Okazaki M et al. Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in japan. BMC Infect Dis 2017; 17: [View Article]
     [Google Scholar]
  64. Cowman S, Burns K, Benson S, Wilson R, Loebinger MR. The antimicrobial susceptibility of non-tuberculous mycobacteria. J Infect Dis 2016; 72:324–331 [View Article]
     [Google Scholar]
  65. Yoshida S, Tsuyuguchi K, Chikamatsu K, Aono A, Takaki A et al. Antimicrobial susceptibility patterns and MICs among non-photochromogenic rapidly growing Mycobacteroides and Mycolicibacterium species. J Med Microbiol 2019; 68:1279–1286 [View Article]
     [Google Scholar]
  66. Griffith DE, Daley CL. Treatment of Mycobacterium abscessus pulmonary disease. Chest 2022; 161:64–75 [View Article]
     [Google Scholar]
  67. Horne D, Skerrett S. Recent advances in nontuberculous mycobacterial lung infections. F1000Res 2019; 8:1710 [View Article]
     [Google Scholar]
  68. Soroka D, Dubée V, Soulier-Escrihuela O, Cuinet G, Hugonnet J-E et al. Characterization of broad-spectrum Mycobacterium abscessus class A β-lactamase. J Antimicrob Chemother 2014; 69:691–696 [View Article] [PubMed]
     [Google Scholar]
  69. Shariati A, Arshadi M, Khosrojerdi MA et al. The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic. Front Public Health 2022; 10:1025633 [View Article]
     [Google Scholar]
  70. Pennington KM, Vu A, Challener D, Rivera CG, Shweta FNU et al. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. J Clin Tuberc Other Mycobact Dis 2021; 24:100244 [View Article] [PubMed]
     [Google Scholar]
  71. Mudde SE, Meliefste HM, Ammerman NC, de Steenwinkel JEM, Bax HI. Omadacycline enhances the in vitro activity of clofazimine against Mycobacterium abscessus. Int J Tuberc Lung Dis 2024; 28:554–556 [View Article] [PubMed]
     [Google Scholar]
  72. Kumar K, Daley CL, Griffith DE, Loebinger MR. Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments. Eur Respir Rev 2022; 31:210212 [View Article] [PubMed]
     [Google Scholar]
  73. Morrisette T, Alosaimy S, Philley JV. Multicenter experience with omadacycline for Mycobacterium abscessus infections. Open Forum Infect Dis 2021; 8:002 [View Article]
     [Google Scholar]
  74. Yang B, Jhun BW, Moon SM, Lee H, Park HY et al. Clofazimine-containing regimen for the treatment of Mycobacterium abscessus lung disease. Antimicrob Agents Chemother 2017; 61:2052–16 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.002005
Loading
Drug susceptibility profiles of Mycobacterium abscessus isolated in the state of São Paulo, 2008–2024
J. Med. Microbiol. 74, 002005 (2025); https://doi.org/10.1099/jmm.0.002005
/content/journal/jmm/10.1099/jmm.0.002005
/content/journal/jmm/10.1099/jmm.0.002005
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error